# Bristol Myers Squibb Type: Company Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bristol-myers-squibb Canonical HTML page: https://getbiobrief.com/entity/bristol-myers-squibb ## Timeline - **2026-03-21**: Litigation Filed — Pomerantz LLP announces the filing of a class action lawsuit against Nektar. - **2026-03-04**: FY 2025 Earnings — Official reporting of full-year financial results and 2026 clinical guidance. - **2026**: Cibotercept Data — Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients. - **2025-Q3**: KER-050 Expansion — Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS. - **2025-Q1**: Capital Infusion — Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials. - **2022-04-18**: Partnership Termination — BMS and Nektar officially end their global clinical development collaboration. - **2022-03-14**: Phase 3 Failure — Lead melanoma trial fails to meet primary endpoints, causing stock to plummet. - **2018-02-14**: BMS Partnership — Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin. ## Recent coverage (9 stories) ### AstraZeneca and BMS in Talks for £300bn Biotech Consolidation Play 2026-08-03 09:56:53 · Sentiment: Neutral · Impact: 9/10 · Sources: 4 The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth. Full story: https://getbiobrief.com/story/astrazeneca-bms-biotech-merger-300bn ### AstraZeneca, BMS Eye $400B Union to Build Cancer Powerhouse 2026-08-02 23:37:29 · Sentiment: Neutral · Impact: 9/10 · Sources: 2 The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership. Full story: https://getbiobrief.com/story/astrazeneca-bms-oncology-pipeline-merger ### Pomerantz LLP Files Class Action Against Nektar Therapeutics Over Disclosures 2026-03-22 02:52:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 3 Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance. Full story: https://getbiobrief.com/story/nektar-therapeutics-class-action-litigation-pomerantz ### Nyxoah and Alumis Miss Q4 Earnings Estimates Amid Scaling R&D Costs 2026-03-20 01:55:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Medical technology firm Nyxoah and immunology specialist Alumis both reported quarterly earnings that fell short of analyst expectations by $0.04 per share. The misses reflect the high capital intensity of late-stage clinical development and the commercial infrastructure build-out required for upcoming product launches. Full story: https://getbiobrief.com/story/nyxoah-alumis-earnings-miss-q4-2026 ### New Cardiovascular Risks Identified in Patients with MCI and Dementia 2026-03-18 16:55:55 · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Recent clinical findings indicate that patients with Mild Cognitive Impairment (MCI) and dementia face a significantly higher risk of developing new cardiovascular indications requiring anticoagulation therapy. This discovery underscores the critical link between cognitive decline and systemic vascular health in the aging population. Full story: https://getbiobrief.com/story/cardiovascular-risks-mci-dementia-anticoagulants ### LOTTE Biologics Targets Global CDMO Expansion at DCAT Week 2026 2026-03-09 07:40:26 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 LOTTE Biologics is set to engage with global pharmaceutical leaders at DCAT Week 2026 in New York, aiming to secure strategic partnerships and showcase its expanding CDMO capabilities. The move underscores the company's aggressive push to become a top-tier global contract manufacturer by leveraging its Syracuse and Songdo facilities. Full story: https://getbiobrief.com/story/lotte-biologics-dcat-week-2026-global-partnerships ### Keros Therapeutics Strengthens TGF-β Pipeline as 2025 Financials Signal Growth 2026-03-04 23:38:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026. Full story: https://getbiobrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis ### Halozyme Q4 2025: ENHANZE Royalty Growth and Opdivo SC Launch Outlook 2026-02-19 04:14:32 · Sentiment: Neutral · Impact: 6/10 · Sources: 3 Halozyme Therapeutics reported robust Q4 2025 results, driven by record royalty revenue from its ENHANZE drug-delivery platform and key partnerships with Roche and Argenx. The company is positioning 2026 as a transformative year, centered on the high-stakes commercial launch of subcutaneous Opdivo in collaboration with Bristol Myers Squibb. Full story: https://getbiobrief.com/story/halozyme-q4-2025-earnings-analysis-enhanze-royalty-growth ### Halozyme Revenue Beats Estimates Amidst Massive $2.44 EPS Miss 2026-02-19 04:10:57 · Sentiment: Bearish · Impact: 6/10 · Sources: 3 Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth. Full story: https://getbiobrief.com/story/halozyme-q4-2025-earnings-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.